Search

everythinglearnresearchcommunity

for

Search:↓

Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.

The conversation discusses using tretinoin cream with minoxidil for hair loss treatment. Users suggest applying them separately to avoid reducing effectiveness.

A user is seeking advice on adding dutasteride to their finasteride regimen to stop DHT-related scalp itch. They have tried selenium sulfide and ketoconazole shampoos with temporary success.

A woman with AGA is using spironolactone, dutasteride, finasteride, oral minoxidil, bicalutamide, and anti-androgenic birth control but still experiences worsening hair loss. Steroid shots temporarily stop her hair shedding, leading her to question her biopsy results.

Obscure hair loss topicals like Alfatradiol, Fluridil, and Stemoxydine are discussed. They may be considered for those not responding well to common treatments like Minoxidil and Finasteride.

The user noticed new baby hairs after using sulforaphane but is still experiencing shedding. They are seeking a supplement to stop shedding, possibly grape seed extract.

Finasteride, minoxidil, dermarolling, and topical antiandrogens are effective for hair regrowth. Future treatments may include CB0301 and hair cloning.

A topical solution called "Multi-Peptide Serum for Hair Density" by The Ordinary Company, which contains several ingredients that are used in alternatives to Minoxidil and was found to have better results than 5% Minoxidil in a study. People who have tried it shared their experiences with the serum as well.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

The conversation is about finding a source for topical valproic acid for hair regrowth. The user mentions PP405 and the unavailability of products from certain suppliers.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

Peptides are being discussed for potential hair loss treatments, but most are not proven effective for this purpose. Minoxidil and finasteride are mentioned as more reliable options for hair growth.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A 29-year-old male in Japan is seeking advice on transitioning Finasteride brands, sourcing Finasteride and Minoxidil without a prescription, and managing chronic scalp inflammation. He is considering adding Minoxidil to his routine and is concerned about diffuse thinning and persistent scalp issues despite following a dermatologist's prescribed treatment.

The user restored their hair using 5% minoxidil liquid, a 5 mg minoxidil pill, and dutasteride, experiencing no side effects. Others shared mixed experiences with dutasteride and finasteride, noting side effects like reduced libido and erection issues.

A 41-year-old male has been using a combination of treatments for hair regrowth, including finasteride, minoxidil, a laser cap, ketoconazole shampoo, and rosemary oil, with some progress noted. He is maintaining his current regimen in hopes of a future miracle drug while considering hair transplants and other treatments like dutasteride and copper peptides.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

A user successfully regrew hair using oral finasteride (1mg daily for 3 years) and topical minoxidil (5% twice daily for 15 years) with no side effects. They highlighted the importance of consistency and patience, crediting finasteride for significant hair improvement.

The user experiences an itchy scalp despite using finasteride and ketoconazole shampoo for hair loss. Suggestions include trying different shampoos, switching to dutasteride, and using topical treatments for inflammation.

Significant hair regrowth was achieved using Minoxidil, Dutasteride, and derma stamping. The user noted improved hair quality and thickness with no side effects.

Low doses of dutasteride are as effective as higher doses for hair regrowth, with fewer side effects. Users find success taking it 2-3 times a week instead of daily.

A 26-year-old reported significant hair regrowth using finasteride daily for six months and topical minoxidil for four months, with no side effects. Others shared mixed experiences, mentioning additional methods like dermarollers and tretinoin.